Pub Date : 2025-02-11DOI: 10.1016/j.tcm.2025.02.004
Philipp von Stein, Christos Iliadis
Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a transformative therapy for mitral regurgitation (MR), addressing the unmet needs of patients unsuitable for surgery. Landmark trials such as EVEREST II, COAPT, and MITRA-FR have established the safety and efficacy of M-TEER, in both patients with primary (PMR) and secondary MR (SMR). Recent trials, including RESHAPE-HF2 and MATTERHORN, have expanded our understanding and refueled discussions regarding patient selection and appropriate treatment indications in SMR. These trials have also contributed to the discussion regarding SMR phenotypes most appropriate for M-TEER. This review summarizes the evidence from pivotal trials, discusses patient selection, device advancements, potential future directions, and outlines ongoing trials that may shape future clinical practice.
{"title":"Transcatheter edge-to-edge repair for mitral regurgitation.","authors":"Philipp von Stein, Christos Iliadis","doi":"10.1016/j.tcm.2025.02.004","DOIUrl":"10.1016/j.tcm.2025.02.004","url":null,"abstract":"<p><p>Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a transformative therapy for mitral regurgitation (MR), addressing the unmet needs of patients unsuitable for surgery. Landmark trials such as EVEREST II, COAPT, and MITRA-FR have established the safety and efficacy of M-TEER, in both patients with primary (PMR) and secondary MR (SMR). Recent trials, including RESHAPE-HF2 and MATTERHORN, have expanded our understanding and refueled discussions regarding patient selection and appropriate treatment indications in SMR. These trials have also contributed to the discussion regarding SMR phenotypes most appropriate for M-TEER. This review summarizes the evidence from pivotal trials, discusses patient selection, device advancements, potential future directions, and outlines ongoing trials that may shape future clinical practice.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-11DOI: 10.1016/j.tcm.2025.02.001
Simon Christie, Michael McGregor, Andrew D Krahn
Cardiac implantable electronic device infections (CIEDI) are an important complication of device implantation associated with significant morbidity, mortality, and cost to the healthcare system. Identifying patients at high risk of device infection is paramount to improving decision making. This includes selecting appropriate devices and implementing adjunctive infection prevention measures, such as antimicrobial envelopes. In addition to meticulous antiseptic surgical technique, several other procedure-related practices can help reduce the risk of device infection. Developing expert centers with multidisciplinary teams capable of device extraction is important to manage patients with CIEDI. In this review, we aim to provide the reader with a succinct overview of CIEDI and summarize new evidence for risk assessment, prevention, diagnosis, and infection management.
{"title":"Cardiac implantable electronic device infection.","authors":"Simon Christie, Michael McGregor, Andrew D Krahn","doi":"10.1016/j.tcm.2025.02.001","DOIUrl":"10.1016/j.tcm.2025.02.001","url":null,"abstract":"<p><p>Cardiac implantable electronic device infections (CIEDI) are an important complication of device implantation associated with significant morbidity, mortality, and cost to the healthcare system. Identifying patients at high risk of device infection is paramount to improving decision making. This includes selecting appropriate devices and implementing adjunctive infection prevention measures, such as antimicrobial envelopes. In addition to meticulous antiseptic surgical technique, several other procedure-related practices can help reduce the risk of device infection. Developing expert centers with multidisciplinary teams capable of device extraction is important to manage patients with CIEDI. In this review, we aim to provide the reader with a succinct overview of CIEDI and summarize new evidence for risk assessment, prevention, diagnosis, and infection management.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-10DOI: 10.1016/j.tcm.2025.01.007
Alexios S Antonopoulos, Alexandros Kasiakogias, Alexandrina Kouroutzoglou, Maria Touloupaki, Alexandros Briasoulis, Efstathios Papatheodorou, Angelos G Rigopoulos, Dimitra Antonakaki, Aggeliki Laina, Konstantinos Tsioufis, Charalambos Vlachopoulos, George Lazaros
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in patients with cardiomyopathies and its clinical management presents a significant challenge. The prevalence of AF varies among cardiomyopathies, with hypertrophic (HCM) and dilated cardiomyopathy (DCM) associated with higher rates of AF. Presence of AF portends increased risk for thromboembolism, heart failure, and cardiovascular morbidity and mortality in patients with cardiomyopathy. The complex genetic substrate in DCM and non-dilated left ventricular cardiomyopathy (NDLVC) contribute to the heterogeneity of AF burden and its sequelae among cardiomyopathy genotypes, necessitating genotype-tailored approach in AF screening and management. Given the lack of validation of traditional risk scores for AF in cardiomyopathies, current clinical recommendations emphasize the importance of comprehensive risk stratification for AF, monitoring for AF, and early initiation of oral anticoagulation for brief AF episodes in specific cardiomyopathy subtypes such as hypertrophic or amyloid cardiomyopathy. AF management includes antiarrhythmic drugs, interventional therapies such as catheter ablation, mitral valve replacement when necessary, and lifestyle modifications to attenuate AF burden and improve quality of life. This review summarizes the current knowledge on the clinical significance, prognostic implications, and treatment of AF among different cardiomyopathy subtypes. We underscore the paradigm shift in AF management advocating for an individualized, subtype-specific, and genotype-aware approach to AF in cardiomyopathies, which is instrumental in improving prognosis and patient-centric care.
{"title":"Atrial fibrillation burden and management in cardiomyopathies: Current evidence and unmet needs.","authors":"Alexios S Antonopoulos, Alexandros Kasiakogias, Alexandrina Kouroutzoglou, Maria Touloupaki, Alexandros Briasoulis, Efstathios Papatheodorou, Angelos G Rigopoulos, Dimitra Antonakaki, Aggeliki Laina, Konstantinos Tsioufis, Charalambos Vlachopoulos, George Lazaros","doi":"10.1016/j.tcm.2025.01.007","DOIUrl":"10.1016/j.tcm.2025.01.007","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in patients with cardiomyopathies and its clinical management presents a significant challenge. The prevalence of AF varies among cardiomyopathies, with hypertrophic (HCM) and dilated cardiomyopathy (DCM) associated with higher rates of AF. Presence of AF portends increased risk for thromboembolism, heart failure, and cardiovascular morbidity and mortality in patients with cardiomyopathy. The complex genetic substrate in DCM and non-dilated left ventricular cardiomyopathy (NDLVC) contribute to the heterogeneity of AF burden and its sequelae among cardiomyopathy genotypes, necessitating genotype-tailored approach in AF screening and management. Given the lack of validation of traditional risk scores for AF in cardiomyopathies, current clinical recommendations emphasize the importance of comprehensive risk stratification for AF, monitoring for AF, and early initiation of oral anticoagulation for brief AF episodes in specific cardiomyopathy subtypes such as hypertrophic or amyloid cardiomyopathy. AF management includes antiarrhythmic drugs, interventional therapies such as catheter ablation, mitral valve replacement when necessary, and lifestyle modifications to attenuate AF burden and improve quality of life. This review summarizes the current knowledge on the clinical significance, prognostic implications, and treatment of AF among different cardiomyopathy subtypes. We underscore the paradigm shift in AF management advocating for an individualized, subtype-specific, and genotype-aware approach to AF in cardiomyopathies, which is instrumental in improving prognosis and patient-centric care.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-10DOI: 10.1016/j.tcm.2025.02.002
Antoine Da Costa, Karim Benali
{"title":"Cardiac implantable electronic device infection: Prevention is better than cure ….","authors":"Antoine Da Costa, Karim Benali","doi":"10.1016/j.tcm.2025.02.002","DOIUrl":"10.1016/j.tcm.2025.02.002","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.07.003
Redwane Rakza , Pierre Groussin , Karim Benali , Nathalie Behar , Philippe Mabo , Dominique Pavin , Christophe Leclercq , Jackson J. Liang , Raphaël P. Martins
Quinidine, the first antiarrhythmic drug, was widely used during the 20th century. Multiple studies have been conducted to provide insights into the pharmacokinetics and pleiotropic effects of Class Ia antiarrhythmic drugs. However, safety concerns and the emergence of new drugs led to a decline in their use during the 1990s.
Despite this, recent studies have reignited the interest in quinidine, particularly for ventricular arrhythmias, where other antiarrhythmics have failed. In conditions such as Brugada syndrome, idiopathic ventricular fibrillation, early repolarization syndrome, short QT syndrome, and electrical storms, quinidine remains a valuable asset. Starting from the European and American recommendations, this comprehensive review aimed to explore the various indications for quinidine and the studies that support its use. We also discuss the potential future of quinidine, including the necessary research to optimize its use and patient selection. Additionally, it addresses the imperative task of mitigating the iatrogenic burden associated with quinidine usage and confronts the challenge of ensuring drug accessibility.
{"title":"Quinidine for ventricular arrhythmias: A comprehensive review","authors":"Redwane Rakza , Pierre Groussin , Karim Benali , Nathalie Behar , Philippe Mabo , Dominique Pavin , Christophe Leclercq , Jackson J. Liang , Raphaël P. Martins","doi":"10.1016/j.tcm.2024.07.003","DOIUrl":"10.1016/j.tcm.2024.07.003","url":null,"abstract":"<div><div>Quinidine, the first antiarrhythmic drug, was widely used during the 20th century. Multiple studies have been conducted to provide insights into the pharmacokinetics and pleiotropic effects of Class Ia antiarrhythmic drugs. However, safety concerns and the emergence of new drugs led to a decline in their use during the 1990s.</div><div>Despite this, recent studies have reignited the interest in quinidine, particularly for ventricular arrhythmias, where other antiarrhythmics have failed. In conditions such as Brugada syndrome, idiopathic ventricular fibrillation, early repolarization syndrome, short QT syndrome, and electrical storms, quinidine remains a valuable asset. Starting from the European and American recommendations, this comprehensive review aimed to explore the various indications for quinidine and the studies that support its use. We also discuss the potential future of quinidine, including the necessary research to optimize its use and patient selection. Additionally, it addresses the imperative task of mitigating the iatrogenic burden associated with quinidine usage and confronts the challenge of ensuring drug accessibility.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 73-81"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.08.006
Muzamil Khawaja , Michael Britt , Affan Rizwan , Jocelyn Abraham , Taylor Nguyen , Uzair Munaf , Muhammad Asad Khan , Hassaan Arshad , Muhamed Munye , Noah Newman , Alfonso Ielasi , Simon Eccleshall , Vassilios S. Vassiliou , Ioannis Merinopoulos , Bernardo Cortese , Chayakrit Krittanawong
Drug-coated balloons have emerged as a promising therapeutic option in the treatment of cardiovascular disease. This review article provides an overview of the concept of drug-coated balloons and their clinical applications in both de novo and treated coronary artery disease. A summary of key clinical trials and registry studies evaluating drug-coated balloons is presented for reference. Overall, this article aims to provide clinicians and researchers with a comprehensive understanding of the current state of drug-coated balloon technology and its implications in clinical practice.
{"title":"Coronary drug-coated balloons: A comprehensive review of clinical applications and controversies","authors":"Muzamil Khawaja , Michael Britt , Affan Rizwan , Jocelyn Abraham , Taylor Nguyen , Uzair Munaf , Muhammad Asad Khan , Hassaan Arshad , Muhamed Munye , Noah Newman , Alfonso Ielasi , Simon Eccleshall , Vassilios S. Vassiliou , Ioannis Merinopoulos , Bernardo Cortese , Chayakrit Krittanawong","doi":"10.1016/j.tcm.2024.08.006","DOIUrl":"10.1016/j.tcm.2024.08.006","url":null,"abstract":"<div><div>Drug-coated balloons have emerged as a promising therapeutic option in the treatment of cardiovascular disease. This review article provides an overview of the concept of drug-coated balloons and their clinical applications in both de novo and treated coronary artery disease. A summary of key clinical trials and registry studies evaluating drug-coated balloons is presented for reference. Overall, this article aims to provide clinicians and researchers with a comprehensive understanding of the current state of drug-coated balloon technology and its implications in clinical practice.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 84-95"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.09.001
Redwane Rakza , Pierre Groussin , Karim Benali , Nathalie Behar , Philippe Mabo , Dominique Pavin , Christophe Leclercq , Jackson J. Liang , Raphaël P. Martins
{"title":"Responses to the letter by Feka et al. regarding oral hydroquinidine as an alternative to intravenous quinidine","authors":"Redwane Rakza , Pierre Groussin , Karim Benali , Nathalie Behar , Philippe Mabo , Dominique Pavin , Christophe Leclercq , Jackson J. Liang , Raphaël P. Martins","doi":"10.1016/j.tcm.2024.09.001","DOIUrl":"10.1016/j.tcm.2024.09.001","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Page 139"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.10.001
Priya Bhardwaj , Stine B. Jacobsen , Jacob Tfelt-Hansen
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease which predisposes to ventricular arrhythmias and sudden cardiac death. Since the introduction of the first diagnostic criteria in 1994, which focused exclusively on right ventricular involvement, diagnostic guidelines have evolved significantly over the past 30 years to encompass the full complexity of the ACM phenotype. In this issue of Trends in Cardiovascular Medicine, Graziano and colleagues review the advancements in ACM diagnostics which emphasizes a comprehensive evaluation of morpho-functional, structural, electrical, and genetic characteristics. The review outlines a three-step clinical approach for diagnosing ACM that involves assessing left and/or right ventricular involvement, identifying the specific ACM subtype, and determining its underlying etiology. This highlights the importance of interdisciplinary teamwork when approaching the complexities of diagnosing ACM and managing the family at risk.
{"title":"Editorial commentary: “Three steps to ACM diagnosis – is it that easy?”","authors":"Priya Bhardwaj , Stine B. Jacobsen , Jacob Tfelt-Hansen","doi":"10.1016/j.tcm.2024.10.001","DOIUrl":"10.1016/j.tcm.2024.10.001","url":null,"abstract":"<div><div>Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease which predisposes to ventricular arrhythmias and sudden cardiac death. Since the introduction of the first diagnostic criteria in 1994, which focused exclusively on right ventricular involvement, diagnostic guidelines have evolved significantly over the past 30 years to encompass the full complexity of the ACM phenotype. In this issue of Trends in Cardiovascular Medicine, Graziano and colleagues review the advancements in ACM diagnostics which emphasizes a comprehensive evaluation of morpho-functional, structural, electrical, and genetic characteristics. The review outlines a three-step clinical approach for diagnosing ACM that involves assessing left and/or right ventricular involvement, identifying the specific ACM subtype, and determining its underlying etiology. This highlights the importance of interdisciplinary teamwork when approaching the complexities of diagnosing ACM and managing the family at risk.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 114-115"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.09.003
Andrew Foy
{"title":"Editorial commentary: Approach to the office patient with apparent resistant or refractory hypertension: Is there a role for renal denervation?","authors":"Andrew Foy","doi":"10.1016/j.tcm.2024.09.003","DOIUrl":"10.1016/j.tcm.2024.09.003","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 105-106"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.tcm.2024.08.003
Richard T. Carrick , Ethan J. Rowin
{"title":"Editorial commentary: Is it finally prime time for artificial intelligence to improve the care of patients with hypertrophic cardiomyopathy?","authors":"Richard T. Carrick , Ethan J. Rowin","doi":"10.1016/j.tcm.2024.08.003","DOIUrl":"10.1016/j.tcm.2024.08.003","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 135-136"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号